Guggenheim Capital’s Arbutus Biopharma ABUS Stock Holding History

Guggenheim Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-36,000	Closed	-$628K	–	3039
2015 Q1	$628K	Buy	+36,000	New	+$737K	﹤0.01%	2445

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Guggenheim Capital's ABUS Position: Q2 2015 in Review

Guggenheim Capital sold out of Arbutus Biopharma (ABUS) in Q2 2015, closing a stake of 36,000 shares — an estimated $628K sold.

Guggenheim Capital first reported a position in ABUS in Q1 2015 and held it in 1 quarter. The position peaked at $628K in Q1 2015. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

Guggenheim Capital reported no remaining Arbutus Biopharma position as of Q2 2015 after selling out during the quarter.
Guggenheim Capital sold 36,000 Arbutus Biopharma shares in Q2 2015, an estimated $628K.
Guggenheim Capital first reported a position in Arbutus Biopharma in Q1 2015 and held it in 1 quarter.
Guggenheim Capital's Arbutus Biopharma position peaked at $628K in Q1 2015.
63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on Guggenheim Capital's 13F filing for Q2 2015, filed 14 Aug 2015.